OK, I don't believe the company you are referencing did anything wrong. In fact they made purchases of another company in April of this year for approximately $250M so as to "enhance the number of immuno-oncology drugs." They also bought-back $5B of their shares from a large pharma that had made a large investment in them. So if this is happening in the marketplace then why hasn't R**N or any other large pharma, purchased/partnered with IPIX for the new SOC drug? Money doesn't seem to be the issue for large pharma.
Market Data 
Markets 
AI
